Mallinckrodt, a little-known drug maker that made headlines recently for various scandals, has resigned from the largest pharmaceutical industry trade group, which is planning steps to convince the public that its members are devoted to research activities.
The move comes as the Pharmaceutical Research & Manufacturers of America tries to respond to ongoing controversy over pricing. The trade group is undergoing what it called a “comprehensive review” of membership criteria in hopes of dispelling criticism that drug makers are price gouging.
In a brief statement, the company would only say that it “routinely evaluates its engagement in trade associations and policy organizations and has concluded that the significant financial and time commitment required as a full PhRMA member outweighs its direct policy value to us at this time.”
About the Author Reprints
